Unlocking Opportunities in the Clinical Oncology Next Generation Sequencing Market: 2025-2034 Forecast Report

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the Clinical Oncology Next Generation Sequencing Industry Market Size Be by 2025?
The market size for next generation sequencing in clinical oncology has seen a swift expansion in the recent past. Projected to catapult from $0.51 billion in 2024 to $0.58 billion in 2025, it is set to experience a 14.8% compound annual growth rate (CAGR). This substantial growth during the historical phase is due to the development in genomic research, discovery of cancer biomarkers, technological progression, and regulatory approvals.

What's the Long-Term Growth Forecast for the Clinical Oncology Next Generation Sequencing Market Size Through 2029?
In the coming years, the clinical oncology next generation sequencing market is projected to experience swift expansion. The market size is anticipated to reach a valuation of $0.95 billion by 2029, growing at a CAGR of 12.9%. The key factors propelling this growth during the forecast period include rising cancer cases, advancements in precision medicine, immuno-oncology, and liquid biopsies. The major trends dominating the forecast period encompass comprehensive genomic profiling (cgp), immuno-oncology, tumor diversification and heterogeneity, and the integration of AI and machine learning.

View the full report here:
https://www.thebusinessresearchcompany.com/report/clinical-oncology-next-generation-sequencing-global-market-report

What Are the Key Growth Drivers Fueling the Clinical Oncology Next Generation Sequencing Market Expansion?
The global increase in cancer incidents is expected to fuel the expansion of the clinical oncology next-generation sequencing market over the forecast period. For instance, data from the National Cancer Institute, a US governmental agency, indicated that in May 2024, approximately 18.1 million individuals in the US had survived cancer. This number is predicted to escalate to 22.5 million by 2032. It is anticipated that by 2040, the annual number of new cancer cases will reach 29.9 million, with cancer-related fatalities projected to grow to 15.3 million. As a result, the rising global prevalence of cancer is projected to propel the growth of the clinical oncology next-generation sequencing market by increasing demand.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3344&type=smp

What Are the Key Trends Driving Clinical Oncology Next Generation Sequencing Market Growth?
Key businesses in the clinical oncology next-generation sequencing market are creating innovative products such as the BenchMark ULTRA PLUS system to boost their market profitability. The BenchMark ULTRA PLUS System is an integral asset for clinical labs, especially those engaged in cancer diagnostics and research. It ensures the precision and efficiency of diagnostic tests, resulting in enhanced patient care. For example, in June 2022, Swiss pharmaceutical company Roche introduced the BenchMark ULTRA PLUS system, which is their most advanced platform for tissue staining. By delivering quick and precise test results, the system enables medical professionals to determine a patient's treatment plan in a timely fashion.

How Is the Clinical Oncology Next Generation Sequencing Market Segmented?
The clinical oncology next generation sequencing market covered in this report is segmented -

1) By Technology: Ion Semiconductor Sequencing, Pyro-Sequencing, Synthesis Sequencing, Real Time Sequencing, Ligation Sequencing, Reversible Dye Termination Sequencing, Nano-Pore Sequencing
2) By Application: Screening, Companion Diagnostics, Other Diagnostics
3) By End User: Hospital Laboratories, Clinical Research Organizations, Diagnostic Laboratories

Subsegments:
1) By Ion Semiconductor Sequencing: Ion Proton System, Ion PGM System, Ion S5 System, Other Ion Semiconductor Sequencing Technologies
2) By Pyro-Sequencing: 454 Pyrosequencing, Other Pyro-Sequencing Technologies
3) By Synthesis Sequencing: Illumina Sequencing Technology, SOLiD Sequencing Technology, Other Synthesis Sequencing Technologies
4) By Real-Time Sequencing: PacBio RS II System, Sequel System, Other Real-Time Sequencing Technologies
5) By Ligation Sequencing: Helicos Single Molecule Sequencing, Other Ligation Sequencing Technologies
6) By Reversible Dye Termination Sequencing: Illumina HiSeq, Illumina NextSeq, Other Reversible Dye Termination Sequencing Technologies
7) By Nano-Pore Sequencing: Oxford Nanopore Technologies (MinION, GridION, PromethION), Other Nano-Pore Sequencing Technologies

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=3344&type=smp

Which Companies Are Leading the Charge in Clinical Oncology Next Generation Sequencing Market Innovation?
Major companies operating in the clinical oncology next generation sequencing market include Thermo Fisher Scientific, Oxford Nanopore Technologies Ltd., QIAGEN N.V., Myriad Genetics Inc., Illumina Inc., F. Hoffmann-La Roche Ltd., PerkinElmer Inc., Agilent Technologies Inc., Pacific Biosciences of California Inc., Caris Life Sciences, Paradigm Diagnostics, GATC Biotech AG, Macrogen Inc., DNASTAR Inc., Exosome Diagnostics Inc., Biomatters Ltd., Partek Inc., Foundation Medicine Inc., Becton inson and Company (BD), Takara Bio Inc., Creative Biolabs, Mogene LC, Knome Inc., Genomatix Software GmbH, CLC bio, GnuBIO Inc., Bio-Rad Laboratories Inc., BGI Genomics Co. Ltd., Guardant Health Inc., Invitae Corporation, Natera Inc., NeoGenomics Laboratories Inc., Sysmex Corporation, Veracyte Inc., Zymo Research Corporation, ArcherDX Inc., Cepheid, Karius Inc., OncoDNA S.A., Personal Genome Diagnostics Inc., PierianDx Inc.

Which Regions Are Leading the Global Clinical Oncology Next Generation Sequencing Market in Revenue?
North America was the largest region in the clinical oncology next-generation sequencing market in 2023. Asia-Pacific was the second largest region in the clinical oncology next-generation sequencing market. The regions covered in the clinical oncology next generation sequencing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3344

"This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work."

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.